Opinion|Videos|February 27, 2025
Future Directions in the Treatment of EGFR-mutated NSCLC: Academic Perspectives and Clinical Pearls.
Author(s)Misako Nagasaka, MD, PhD
The panelist discusses how, expanding clinical trials, biomarker testing, and financial support improves access to emerging EGFR therapies. Novel bispecific antibodies and ADCs may shift treatment. Key insights include resistance monitoring and proactive AE management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are opportunities for improving patient access to emerging therapies and optimal care?
- What novel approaches are in development that could impact the treatment landscape?
- What clinical pearls can you share for providers treating EGFR-mutated Advanced/Metastatic NSCLC?
Advertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
5